Literature DB >> 3768243

Partial metabolic clearances as determinants of the oral bioavailability of propranolol.

T Walle, U K Walle, L S Olanoff, E C Conradi.   

Abstract

The objective of this study was to determine the relationships between the total oral clearance of propranolol and the partial clearances through its primary metabolic pathways, i.e. glucuronidation, side-chain oxidation and ring oxidation. Seven young, white males were given single 80 mg oral doses of the drug together with tritium-labelled propranolol. Plasma propranolol was measured by GC/MS and fourteen metabolites were measured in urine by h.p.l.c. with radiometric detection. The total oral clearance of propranolol in these subjects varied about three-fold, from 27.5 to 71.4 ml min-1 kg-1. The clearance through glucuronidation was very similar in all subjects, ranging from 6.8 to 9.9 ml min-1 kg-1. The clearance through side-chain oxidation varied 2.4-fold, from 10.9 to 25.8 ml min-1 kg-1. Increased clearance through this pathway correlated with increased total oral clearance (r = 0.84; P less than 0.02). The clearance through ring oxidation varied as much as 5.6-fold, from 7.5 to 41.8 ml min-1 kg-1. Increased clearance through this pathway correlated highly with increased total oral clearance (r = 0.94; P less than 0.002). These observations indicate that the intersubject variability in the oral clearance of propranolol in young, white males is due mainly to differences in the activity of the ring oxidation pathway, to some extent in the side-chain oxidation pathway, but not to differences in the glucuronidation pathway. The partial metabolic clearance approach adopted in this study may be useful in the investigation of factors influencing the oral bioavailability of propranolol.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768243      PMCID: PMC1401138          DOI: 10.1111/j.1365-2125.1986.tb02893.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Simultaneous determination of propranolol and 4-hydroxypropranolol in plasma by mass fragmentography.

Authors:  T Walle; J Morrison; K Walle; E Conradi
Journal:  J Chromatogr       Date:  1975-11-26

2.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  The disposition of propranolol. I. Elimination during oral absorption in man.

Authors:  D G Shand; R E Rangno
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

4.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

5.  The predictable relationship between plasma levels and dose during chronic propranolol therapy.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1978-12       Impact factor: 6.875

6.  Biological determinants of propranolol disposition in man.

Authors:  D M Kornhauser; A J Wood; R E Vestal; G R Wilkinson; R A Branch; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

7.  Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial.

Authors:  T Walle; R P Byington; C D Furberg; K M McIntyre; P S Vokonas
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

8.  Presystemic and systemic glucuronidation of propranolol.

Authors:  T Walle; T C Fagan; E C Conradi; U K Walle; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

Review 9.  Clinical pharmacokinetics of propranolol.

Authors:  P A Routledge; D G Shand
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

10.  Direct measurement of propranolol bioavailability during accumulation to steady-state.

Authors:  A J Wood; K Carr; R E Vestal; S Belcher; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

View more
  6 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias.

Authors:  U M Birgersdotter; W Wong; J Turgeon; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

3.  Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Authors:  C Funck-Brentano; H K Kroemer; H Pavlou; R L Woosley; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

4.  Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity.

Authors:  S V Otton; E M Gillam; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

5.  Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.

Authors:  M A Laurent-Kenesi; C Funck-Brentano; J M Poirier; D Decolin; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

6.  Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol.

Authors:  Ebrahim Salehifar; Shima Ebrahim; Mohammad-Reza Shiran; Fatemeh Faramarzi; Hossein Askari Rad; Razieh Avan; Asadollah Mohseni Kiasari; Pouneh Ebrahimi
Journal:  Adv Pharm Bull       Date:  2017-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.